▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #901 by analyst upside · 2026-11-14
ASMB
Assembly Biosciences, Inc.
Healthcare · Market Cap $430M · P/E 19.4x
ANALYST PRICE TARGET
+142.4%
implied upside to consensus target
Current Price $21.12
Consensus Target $51.2
Bull Target $62.0
Bear Target $43.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
5
Hold
0
Sell
0
52-Week Low $19.2
52-Week High $39.71
YTD Return -37.4%
FUNDAMENTALS
Market Cap $430M
P/E Ratio (TTM) 19.4x
Forward P/E N/A
EPS (TTM) $1.09
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $67M
Profit Margin -16.6%
52-WEEK RANGE
52-Week Low $19.2
52-Week High $39.71
Current Price $21.12
Bear Target $43.0
Bull Target $62.0
● Now $21.12 ● Target $51.2
TRADING DATA
Avg Volume 308K
YTD Return -37.4%
Analyst Count 5
Consensus Buy
Upside to Target +142.4%
Last Updated 2026-11-14

ANALYST SUMMARY

Assembly Biosciences, Inc. (ASMB) is currently trading at $21.12 with a Wall Street consensus price target of $51.2, implying potential upside of 142.4% over the next 12 months. 5 analysts currently cover ASMB, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $62.0, while the most cautious has a target of $43.0.

ASMB operates in the Healthcare sector with a market capitalisation of $430M. The stock is down 37.4% year-to-date and is currently trading near the lower end of its 52-week range of $19.2 – $39.71.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ASMB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS - Reiterated
Buy → Buy 2026-11-03 33% win rate (6 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-09-01 Building track record
UBS ● Initiated
Buy 2026-09-01 33% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-08-18 31% win rate (48 calls)
Mizuho - Reiterated
Outperform → Outperform 2026-06-15 Building track record
Guggenheim reit
Buy → Buy 2026-05-28 62% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-05-04 31% win rate (48 calls)
Guggenheim - Reiterated
Buy → Buy 2026-04-06 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
53
out of 100
Coverage depth
14/30
Consensus clarity
12/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →